Protas is the new host organisation for the Good Clinical Trials Collaborative. The Collaborative, led by Martin Landray, has developed guidance to set and promote a new international benchmark of scientific rigour, ethical integrity, efficiency and quality for randomized controlled trials (RCTs).
The guidance describes the key principles of RCTs: what makes an RCT good in its design and analysis, as well as ethical and social value; and why this is so. This guidance aims to enable those involved in RCTs to work out for themselves how to design and deliver their particular RCT in their particular setting.
Launched in June 2020 and supported by grants from Wellcome and the Bill & Melinda Gates Foundation, the Good Clinical Trials Collaborative has brought together a wide range of individuals and organizations with an interest in and role to play in the design, delivery, analysis and reporting of randomized trials, and in implementing the results.
This includes those who fund, regulate, design, deliver, or are responsible for such trials, those who provide audits and quality assurance functions, research organizations, clinicians, participants, ethicists, and lay health advocates. It includes those from a wide variety of sectors (industry, academia, government, charitable, non-governmental organizations, participant and public groups) and global settings.
You can keep up to date with the Collaborative’s work on goodtrials.org, where the guidance is available in six major languages.